Spotlight on ixazomib: potential in the treatment of multiple myeloma

Despite the significant therapeutic advances achieved with proteasome inhibitors (PIs) such as bortezomib and carfilzomib in prolonging the survival of patients with multiple myeloma, the development of drug resistance, peripheral neuropathy, and pharmacokinetic limitations continue to pose major ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Muz, Barbara, Ghazarian, Rachel Nicole, Ou, Monica, Luderer, Micah John, Kusdono, Hubert Daniel, Azab, Abdel Kareem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714737/
https://www.ncbi.nlm.nih.gov/pubmed/26811670
http://dx.doi.org/10.2147/DDDT.S93602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714737/
https://www.ncbi.nlm.nih.gov/pubmed/26811670
http://dx.doi.org/10.2147/DDDT.S93602

Ejemplares similares